Our Research

Northern California Retina Vitreous Associates (NCRVA) is nationally recognized and active in clinical trials for the past thirty years. We are proud to have been a part of the landmark studies that brought forth FDA-approved, vision saving treatments, such as Lucentis (ranibizumab, Genentech), Eylea (aflibercept, Regeneron), Ozurdex (dexamethasone implant, Allergan), Vabysmo (faricimab, Genentech), and photodynamic therapy (visudyne, Novartis) for retinal diseases including age related macular degeneration (wet AMD), retinal vein occlusions, and diabetic macular edema. 

The physicians at NCRVA are dedicated to bring you the most advanced surgical and medical care available. Our research team is committed to carefully selecting well-designed, safe clinical studies that offer promising and exciting new treatments for our patients. Our clinical trials are a valuable opportunity for patients to access novel treatments for retinal diseases.

If you have been diagnosed with a retinal condition and would like to learn more about the clinical trials that our practice participates in, you can reach our Research Team directly by either calling 650-963-3465 or emailing us at ros@ncrva.com